Drug Discovery Informatics Market Size, Share & Trends Analysis Report By Mode (In-house, Outsourced), By Workflow (Discovery, Development), By Services (Sequence Analysis Platforms, Docking), And Segment Forecasts, 2021 - 2028

Report Overview

The global drug discovery informatics market size was valued at USD 2.39 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 11.3% from 2021 to 2028. The drug discovery informatics market is set to gain momentum in the coming years due to advancements in high-performance computing & web services, increasing adoption of in-silico modeling tools, the growing volume of drug discovery data, and rising demand for novel medicine moieties. The launch of advanced drug discovery information technology is set to intensify the industry competition. For instance, in January 2021, Certara, Inc. launched Simcyp Physiologically-based Pharmacokinetic (PBPK) Simulator platform version 20. The new models help in assessing and analyzing the drug action during pregnancy and lactation.

In addition, it helps the customers with critical decisions regarding optimizing medicine safety and efficacy profile. Companies are also increasingly adopting informatics solutions to shorten the long drug discovery timeline. For instance, in December 2020, Curve Therapeutics Ltd. implemented the CDD Vault platform for managing its genetically encoded Microcycle platform. It is a ubiquitous hosted platform suitable for applications across pharmaceutical, biotechnology, and academic institutes for securing and seamless sharing of data in real-time, thereby facilitating collaborative discoveries.

Moreover, the accelerated Covid-19 drug discovery around the world is further contributing to the market growth. For instance, for providing fast-track solutions, scientists performed virtual screening using medicine from the DrugBank, for targeting the viral proteins and human ACE2 receptors. These studies were based on in silico tools for screening small molecules that have the potential usage in drug discoveries against Covid-19.

Similarly, companies are developing several web services & solutions for supporting various steps of drug development for Covid-19. For instance, in June 2020, the IBM visual molecular explorer platform explored a selected set of the generated molecules targeting the coronavirus (SARS-CoV-2). The open-source sharing of the AI-generated artefacts in the explorer helped in the initial stages of optimal medicine designing.

Workflow Insights

The discovery informatics dominated the market in 2020 with a revenue share of 59.19% due to a major focus on the development of precision medicines. Precision medicine involves specific medical care based on the patients’ genetic and molecular profiling. Companies, such as PerkinElmer, Inc., provide discovery informatics solutions for leveraging analytics for rapid drug discovery.

In addition, the governments in several developing countries are promoting the application of bioinformatics for rapid medicine discovery. For instance, in July 2020, the government of India launched Drug Discovery Hackathon (DDH). It is a training program for promoting the discovery of an effective molecule against the Covid-19 virus with the application of drug discovery informatics tools that have potential applications in identification, validation, and designing & molecule synthesis of the lead molecule.

The drug development workflow segment is expected to register the fastest CAGR of 11.69% from 2021 to 2028 owing to an increasing number of medicine candidates in the pipeline for pharmaceutical companies. These tools are used to perform specific tasks in clinical trial designing for promising the greatest improvement of overall trial performance.

Mode Insights

The outsourced mode segment dominated the market in 2020 with a revenue share of 51.21%. The segment will expand further at a steady CAGR during the forecast period on account of an increasing number of partnerships between pharmaceutical companies and contract development and manufacturing organizations (CDMOs). Contract Research Organizations (CROs) are involved in the creation of reports on new drug entities that are subsequently used by the sponsor or drug manufacturer for submitting to the U.S. FDA.

There are benefits when pharmaceutical & biotechnology companies partner with a CRO that has the same informatics solution. The shared informatics platform between the CRO and companies helps in monitoring the progress of studies in the same way as their internal studies. This helps the company in cost-saving and productivity gain, which is expected to offer the market entities immense profitable opportunities.

The in-house mode segment is expected to witness the fastest CAGR of 11.73% from 2021 to 2028 due to the increasing adoption of informatics by large-scale companies for drug discovery owing to its advantages, such as providing direct access to information from a wide variety of sources, avoiding lengthy data compilation & reformatting, and helps in combining cross-disciplinary information.

Services Insights

The sequence analysis platforms emerged as a dominant segment with a revenue share of 35.22% in 2020. The segment will retain the dominant position registering the fastest CAGR over the forecast period. Bioinformatic solutions are widely employed for the development of primary & secondary databases of nucleic acid, protein as well as other biomolecule sequences. With the application of informatics software, mining and warehousing of genome sequencing is done for identifying genes and targeted proteins, which will help in the development of potential drugs.

In addition, basic drug discovery research requires the employment of different databases along with sequence analysis tools, such as CLUSTALW, BLAST, and FASTA. Also, the launch of new and advanced software is contributing to the segment growth. For instance, in July 2019, Certara launched a new version of D360, a scientific informatics platform (version 19.6) for drug discovery & development. The platform enables alignment, representation, and analysis of small sections of proteins and peptide sequences.

The informatics platform enables users to arrange peptide sequences based on color code by property. Molecular modeling is increasingly gaining popularity owing to its wide application in the drug discovery process. These tools are applied for the modeling and simulation of biological systems and small molecules for understanding & predicting their behavior at a molecular level. In addition, they accelerate the cost-efficiency of hit discovery and hit-to-lead optimization.

Regional Insights

North America accounted for the largest market share of 39.30% in 2020; growth in the region can be attributed to several factors, such as high incidence of infectious diseases, rapid adoption of new & advanced tools for R&D, and the presence of prominent players. Moreover, companies in the region are focusing on joint ventures and research collaborations, which will boost the market growth in the coming years.

For instance, in December 2020, Atomwise Inc. unveiled a growing portfolio of joint venture companies including vAirus, OrganAi, and A2i Therapeutics, with programs spanning infectious disease, immunology, oncology, clotting disorders, and neuroscience. Asia Pacific is projected to be the fastest-growing regional market from 2021 to 2028.

Key Companies & Market Share Insights

Key players are increasingly engaging in collaborations with other companies, research institutes, and clinical research organizations for promoting rapid drug development. For instance, in March 2020, Charles River Laboratories International, Inc. entered in partnership with Deciphex. Deciphex’s Patholytix Preclinical platform will help in maximizing pathologist productivity and delivering data faster to clients. This helped expand the company’s portfolio in the market. Some key participants in the global drug discovery informatics market include:

• Certara

• Boehringer Ingelheim International GmbH

• Infosys Ltd.

• Charles River Laboratories

• Collaborative Drug Discovery, Inc.

• Eurofins DiscoverX Products

• Jubilant Biosys

• Selvita

• Novo Informatics Pvt. Ltd.

• ChemAxon Ltd.

• Albany Molecular Research Inc.

• Oracle

• Accenture

• Agilent Technologies, Inc.

• Illumina, Inc.

Drug Discovery Informatics Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global drug discovery informatics market report on the basis of workflow, mode, services, and region:

• Workflow Outlook (Revenue, USD Million, 2017 - 2028)

  • Discovery Informatics

    • Identification, Validation, & Assay Development Informatics

    • Lead Generation

  • Development Informatics

    • Lead Optimization

    • FHD Preparation

    • Phase IA

    • Phase IB/2

• Mode Outlook (Revenue, USD Million, 2017 - 2028)

  • Outsourced

  • In-house

• Services Outlook (Revenue, USD Million, 2017 - 2028)

  • Sequence Analysis Platforms

  • Molecular Modeling

  • Docking

  • Clinical Trial Data Management

  • Other Services

• Regional Outlook (Revenue, USD Million, 2017 - 2028)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

  • Latin America

    • Brazil

  • Middle East & Africa

    • South Africa